Vol 61, No 9 (2004)
Other
Published online: 2005-12-12
Submitted: 2012-12-28
Get Citation

High-dose statin and COX-2 inhibitor therapy rapidly decreases C-reactive protein level in patients with unstable angina

Michał Chyrchel, Dariusz Dudek, Stanisław Bartuś, Jacek Legutko, Grzegorz Heba, Jacek Dubiel
Kardiol Pol 2004;61(9):218-221.
Vol 61, No 9 (2004)
Other
Published online: 2005-12-12
Submitted: 2012-12-28

Abstract

Background and aim: Elevated levels of C-reactive protein (CRP) are associated with an increased risk of coronary events. The levels of CRP and other inflammatory markers are significantly elevated in patients with unstable angina. We hypothesised that a high-dose statin therapy alone or with cyclooxygenase-2 (COX-2) inhibitors, administered before coronary diagnostic or invasive procedures, can attenuate CRP elevation after the procedure and, consequently, more effectively reduce the rate of coronary events.
Methods: All patients with unstable angina in class III and IIB according to Braunwald classification were considered for inclusion in the present study. Finally, 60 patients with elevated CRP level (>3 mg/l) were randomised to three groups of pharmacological treatment before coronary angiography and subsequent angioplasty. Patients from group A received placebo, patients from group B - 80 mg of atorvastatin, and patients from group C - 80 mg of atorvastatin and 25 mg of rofecoxib. The levels of CRP were measured at baseline, after 3 days of therapy and 48 hours after invasive coronary procedure.
Results: The mean baseline CRP level in group A was 5.67±2.82 mg/l, in group B - 4.7±1.32 mg/l, and in group C - 6.78±2.56 mg/l (NS). After three days of pharmacological treatment, the mean CRP level was 5.82±2.69 mg/l in group A (NS compared with baseline) and was significantly reduced in group B to 2.5±1.37 mg/l and in group C to 3.01±1.57 mg/l (p

Abstract

Background and aim: Elevated levels of C-reactive protein (CRP) are associated with an increased risk of coronary events. The levels of CRP and other inflammatory markers are significantly elevated in patients with unstable angina. We hypothesised that a high-dose statin therapy alone or with cyclooxygenase-2 (COX-2) inhibitors, administered before coronary diagnostic or invasive procedures, can attenuate CRP elevation after the procedure and, consequently, more effectively reduce the rate of coronary events.
Methods: All patients with unstable angina in class III and IIB according to Braunwald classification were considered for inclusion in the present study. Finally, 60 patients with elevated CRP level (>3 mg/l) were randomised to three groups of pharmacological treatment before coronary angiography and subsequent angioplasty. Patients from group A received placebo, patients from group B - 80 mg of atorvastatin, and patients from group C - 80 mg of atorvastatin and 25 mg of rofecoxib. The levels of CRP were measured at baseline, after 3 days of therapy and 48 hours after invasive coronary procedure.
Results: The mean baseline CRP level in group A was 5.67±2.82 mg/l, in group B - 4.7±1.32 mg/l, and in group C - 6.78±2.56 mg/l (NS). After three days of pharmacological treatment, the mean CRP level was 5.82±2.69 mg/l in group A (NS compared with baseline) and was significantly reduced in group B to 2.5±1.37 mg/l and in group C to 3.01±1.57 mg/l (p
Get Citation

Keywords

unstable angina - inflammation - statins - cox-2 inhibitor

About this article
Title

High-dose statin and COX-2 inhibitor therapy rapidly decreases C-reactive protein level in patients with unstable angina

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 61, No 9 (2004)

Pages

218-221

Published online

2005-12-12

Bibliographic record

Kardiol Pol 2004;61(9):218-221.

Keywords

unstable angina - inflammation - statins - cox-2 inhibitor

Authors

Michał Chyrchel
Dariusz Dudek
Stanisław Bartuś
Jacek Legutko
Grzegorz Heba
Jacek Dubiel

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl